Session Information
Session Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis
Session Type: Abstract Submissions (ACR)
Background/Purpose: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD) that influences the prognosis of the disease. Transfusion related acute lung injury is defined as an acute lung injury associated with blood transfusion; one of its causes is thought to be anti-HLA antibody. Here, we investigated the anti-HLA antibody profiles to determine whether they may be useful for diagnosing RA-ILD.
Methods: Anti-HLA antibody levels were analyzed using the Lambda Array Beads Multi-Analyte System (LABScreen Mixed Assay, One Lambda, Canoga Park, CA), using a LabScan 100 system (Luminex, Austin, TX), in 34 RA patients with or without RA-ILD. This study was reviewed and approved by the ethics committees of each participating institute. Informed consent was provided by all subjects.
Results: Average anti-major histocompatibility complex class I-related chain A (MICA) antibody levels were higher in RA patients with ILD than in those without (P=0.0013, Mann-Whitney’s U test). Average anti-HLA class I or class II antibody levels were not significantly different between RA patients with or without ILD (P=0.6419 and 0.2486, respectively). The ratio of (average anti-MICA antibody levels) / (average anti-HLA class I antibody levels) was increased in RA patients with ILD than in those without (P=4.47X10-5). The area under the curve value of receiver operating characteristic curves of the ratio was 0.912. The optimized cut-off level of the ratio was determined for RA-ILD, and the specificity and the sensitivity were 88.2% and 82.4%, respectively.
Conclusion: To the best of our knowledge, this is the first report of anti-HLA antibody profiles in RA-ILD. The ratio of (average anti-MICA antibody levels) / (average anti-HLA class I antibody levels) could be a better marker for diagnosing RA-ILD. Further large-scale studies would provide a possibility of generating better markers for RA-ILD.
Disclosure:
H. Furukawa,
The Japan Research Foundation for Clinical Pharmacology,
2,
The Takeda Science Foundation ,
2,
The Nakatomi Foundation,
2,
The Daiwa Securities Health Foundation ,
2,
Mitsui Sumitomo Insurance Welfare Foundation,
2;
S. Oka,
None;
K. Shimada,
None;
A. Komiya,
None;
N. Fukui,
None;
N. Tsuchiya,
None;
S. Tohma,
Pfizer Japan Inc., Eisai Co., Ltd, and Chugai Pharmaceutical Co., Ltd,
2.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-major-histocompatibility-complex-class-i-related-chain-a-mica-antibodies-in-rheumatoid-arthritis-patients-with-interstitial-lung-disease/